MedTrace Logo

ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma

NCT06149390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347

Last updated 2023-11-29

No results posted yet for this study

Summary

To compare the effectiveness of autologous hematopoietic stem cell transplantation and chemotherapy as first-line consolidation therapy after obtaining a complete therapeutic response in T-cell lymphoma through a multicenter retrospective real-world study in China.

Conditions

  • T-cell Lymphoma Adults

Interventions

DRUG

consolidation with ASCT

high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion

Sponsors & Collaborators

  • Peking University People's Hospital

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xiaodong Mo · Peking University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2022-01-01
Completion
2023-07-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06149390 on ClinicalTrials.gov